iBio, Inc. Common Stock

Day range

$0.69 – $0.73

Open

$0.73

Prev close

$0.72

Volume

382.61K

Market cap

$46.16M

Shares out

64.31M

P/E

—

P/S

463.01

P/B

0.54

P/FCF

—

ROE

-28.1%

ROA

-24.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentOct 19, 2026

  The following two (2) nominees were elected as Class III directors of the Company's Board of Directors ... each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders: 1. William Clark ... 2. Gary Sender.

• Clinical trial resultsOct 13, 2026

  On October 13, 2026, iBio, Inc. issued a press release highlighting preclinical body-composition data from its eight week obese non-human primate ("NHP") study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. At week 8, fat accounted for 93% of the weight lost by NHPs given a single dose of IBIO-610 alongside twice-weekly semaglutide, compared with 77% for NHPs given semaglutide alone.

• Investor presentationSep 14, 2026

  iBio, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

• Executive officer appointmentAug 4, 2026

  Effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. (the "Company"). Dr. Molly Carr, M.D., age 59, is a physician executive with extensive experience in the biotechnology and pharmaceutical industries.

• Shareholder meeting noticeJul 17, 2026

  iBio, Inc. (the "Company") currently plans to hold its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") on October 14, 2026. The Company intends to set the record date for determining the stockholders of record who will be entitled to vote at the 2026 Annual Meeting as the close of business on September 1, 2026.

Days to cover

6.2

Short interest

4.2M

Avg volume

681.57K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
  positiveGlobeNewswire Inc.· Aug 28, 2026
• iBio Announces $26 Million Private Placement
  positiveGlobeNewswire Inc.· Jan 9, 2026
• iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
  positiveGlobeNewswire Inc.· Oct 23, 2025
• iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
  positiveGlobeNewswire Inc.· Jun 24, 2025
• iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
  positiveGlobeNewswire Inc.· Jan 2, 2025